COVID -19: REPLICATION INHIBITORS AS PROMISING THERAPY FOR SYMPTOMATIC PATIENTS
Keywords:COVID-19, Coronavirus, Remdesivir, Molnupiravir, Paxlovid
COVID-19 is unprecedented pandemic threading the mankind existence in the recent time, with globally reported (256,966,237) confirmed cases, including (5,151,643) death, as of 22 of November 2021(WHO. 2021). The COVID-19 vaccine doses administered globally were (7,408,870,760) doses as of 22 of November 2021 (WHO. 2021).
Strategy to face this serious threat include prevention of getting infection and rational treatment of symptomatic infected ones. Treatment can adopt one or all of the three strategies; prohibiting the virus from entry into the human cells, halt replication of the virus inside the human cells, and neutralizing the inflammatory and other effects of the virus pathogencity.
Replication inhibitors are important tool in the tools box against COVID-19, however they are not substitute for vaccination against COVID-19 and other adopted preventive measurements. Still prevention is the best medicine for any disease.
The aim of this review is to further explore the replication inhibitors as emerging tools for treatment of symptomatic cases of COVID-19. Many encouraging results have emerged from recent clinical trials. This may help to bridge the gap in existence knowledge and stimulate further discussion to enhance conducting more clinical trials for the treatment of COVID-19 and repurpose already existing other viral replicating indictors for treatment of COVID-19. Remdesivir, Molnupiravir and Paxlovid are promising viral replicating inhibitors drugs for treatment of symptomatic COVID-19 patients. Since Molnupiravir and Paxlovid are given orally as five days short course, are significantly of great value for low-income countries
Andri Frediansyaha, Ruchi Tiwari, Khan Sharund, Kuldeep Dhamae, and Harapan Harapan. (2021) Antivirals for COVID-19: A critical review. Clinical Epidemiology and Global Health. 9: 90-98. Retrieved from https://doi.org/10.1016/j.cegh.2020.07.006 DOI: https://doi.org/10.1016/j.cegh.2020.07.006
Bahman Yousefi , Saeid Valizadeh, Hadi Ghaffari, Azadeh Vahedi ,Mohsen Karbalaei, and Majid Eslami. (2020).A global treatments for coronaviruses including COVID‐19J Cell Physiol.;235:9133-9142. Retrieved from https://doi.org/10.1002/jcp.29785 DOI: https://doi.org/10.1002/jcp.29785
Bergmann and Silverman. (2020) .COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. Cleveland Clinic Journal of Medicine ; Volume 87 . Number 6 . Retrieved from https://doi.org/10.3949/ccjm.87a.20047 DOI: https://doi.org/10.3949/ccjm.87a.20047
Brandon Malone and Elizabeth A. (2021) Campbell. Molnupiravir: coding for catastrophe. Nature Structural & Molecular Biology | VOL 28 | SepTeMbeR 2021 | 706-711 | www.nature.com/nsmb. Retrieved from https://doi.org/10.1038/s41594-021-00657-8 DOI: https://doi.org/10.1038/s41594-021-00657-8
ClinicalTrials.gov Identifier NCT04292730 : (2021). A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment.. Last Update Posted : January 26, 2021.
ClinicalTrials.gov Identifier: NCT04292899 . (2020).A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19. Last Update Posted : December 31, 2020
Cox, R. M. et al. (2021).Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets Nature Microbiol. 6, 11-18 . Retrieved from https://doi.org/10.1038/s41564-020-00835-2 DOI: https://doi.org/10.1038/s41564-020-00835-2
Cui J, Li F, Shi ZL. (2019). Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181-192. Retrieved from https://doi.org/10.1038/s41579-018-0118-9 DOI: https://doi.org/10.1038/s41579-018-0118-9
Denisa Bojkova, Marco Bechtel, Katie-May McLaughlin, et al (2020).Aprotinin Inhibits SARS-CoV-2 Replication. Cells, 9, 2377. Retrieved from https://doi.org/10.3390/cells9112377 DOI: https://doi.org/10.3390/cells9112377
EMA. (2020). European Medicine Agency (EMA).First COVID-19 treatment recommended for EU authorization. Press release 25/06/2020
Elisabeth Mahase. (2021)b. Covid-19: Pfizer 's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ 2021;375:n2713. Retrieved from https://doi.org/10.1136/bmj.n2713 DOI: https://doi.org/10.1136/bmj.n2713
Elisabeth Mahase (2021). b.. Covid-19: UK becomes first country to authorise antiviral molnupiravir. BMJ 2021;375:n2697. Retrieved from https://doi.org/10.1136/bmj.n2697 DOI: https://doi.org/10.1136/bmj.n2697
HarapanHarapan. Naoya Itoh. (2020) Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health.; 13(5): 667-673. Retrieved from https://doi.org/10.1016/j.jiph.2020.03.019 DOI: https://doi.org/10.1016/j.jiph.2020.03.019
Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. ( 2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis.. 91:264-266. Retrieved from https://doi.org/10.1016/j.ijid.2020.01.009 DOI: https://doi.org/10.1016/j.ijid.2020.01.009
John H. Beigel, Kay M. Tomashek, Lori E. Dodd, Aneesh K. Mehta, Barry S. Zingman, Andre C. Kalil, Elizabeth Hohmann, Helen Y. Chu, Annie Luetkemeyer, Susan Kline, Diego Lopez de Castilla, Robert W. Finberg, et al (2020). For the ACTT-1 Study Group Members..Remdesivir for the Treatment of Covid-19 - Final Report .N Engl J Med; 383:1813-1826. Retrieved from https://doi.org/10.1056/NEJMoa2007764 DOI: https://doi.org/10.1056/NEJMoa2007764
Julia Magden, Leevi Kääriäinen, and Tero Ahola. (2005). Inhibitors of virus replication: recent developments and prospects .Appl Microbiol Biotechnol. 66(6): 612-621. Retrieved from https://doi.org/10.1007/s00253-004-1783-3 DOI: https://doi.org/10.1007/s00253-004-1783-3
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. (2020) The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. Retrieved from https://doi.org/10.1101/2020.02.02.20020016 DOI: https://doi.org/10.7326/M20-0504
Leon Calya, Julian D. Drucea, Mike G. Cattona, David A. Jans, Kylie M. Wagstaﬀb. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 178 ; 104787. Retrieved from https://doi.org/10.1016/j.antiviral.2020.104787 DOI: https://doi.org/10.1016/j.antiviral.2020.104787
Mark Andrew White, Wei Lin, and Xiaodong Cheng. (2020). Discovery of COVID-19 Inhibitors Targeting the SARS-CoV‑2 Nsp13 Helicase . J. Phys. Chem. Lett. 11, 9144−9151. Retrieved from https://doi.org/10.1021/acs.jpclett.0c02421 DOI: https://doi.org/10.1021/acs.jpclett.0c02421
Norio Yamamoto, Shutoku Matsuyama, Tyuji Hoshino, and Naoki Yamamoto. (2020). Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. BioRxiv preprint. Retrieved from https://doi.org/10.1101/2020.04.06.026476 DOI: https://doi.org/10.1101/2020.04.06.026476
Philip V'kovski, Annika Kratzel, Silvio Steiner, Hanspeter Stalder and Volker Thiel (2021). Coronavirus biology and replication: implications for SARS- CoV-2.Nature Reviews Microbiology volume 19 .157. Retrieved from https://doi.org/10.1038/s41579-020-00468-6 DOI: https://doi.org/10.1038/s41579-020-00468-6
Reza Ghanbari, Ali Teimoori, Anahita Sadeghi, Ashraf Mohamadkhani, Sama Rezasoltani, Ebrahim Asadi, Abolghasem Jouyban & Susan CJ Sumner. (2020). Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiol. 15(18), 1747-1758. Retrieved from https://doi.org/10.2217/fmb-2020-0120 DOI: https://doi.org/10.2217/fmb-2020-0120
Sarah Lam, Andrew Lombardi, and Aviv Ouanounou. (2020) COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol.; 886: 173451. Retrieved from https://doi.org/10.1016/j.ejphar.2020.173451 DOI: https://doi.org/10.1016/j.ejphar.2020.173451
Schoeman, D., Fielding, B.C. (2019). Coronavirus envelope protein: current knowledge. Virol J ; 16, 69. Retrieved from https://doi.org/10.1186/s12985-019-1182-0 DOI: https://doi.org/10.1186/s12985-019-1182-0
Sheahan, T. P. et al. (2020). An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Sci. Transl. Med. 12. Retrieved from https://doi.org/10.1126/scitranslmed.abb5883 DOI: https://doi.org/10.1126/scitranslmed.abb5883
Subramanian Boopathi. Adolfo B Poma. PonmalaiKolandaivel (2020) Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral Drug Promises and Rule Out Against Its Treatment. J BiomolStruct Dyn;1-10. Retrieved from https://doi.org/10.1080/07391102.2020.1758788 DOI: https://doi.org/10.1080/07391102.2020.1758788
Suliman Khan. Rabeea Siddique. Muhammad Adnan Shereen. Ashaq Ali. Jianbo Liu. Qian Bai. Nadia Bashir. and MengzhouXue. ( 2020) Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. J Clin Microbiol.; 58(5): e00187-20. Retrieved from https://doi.org/10.1128/JCM.00187-20 DOI: https://doi.org/10.1128/JCM.00187-20
WHO (2020). Retrieved from https://covid19.who.int/
William Fischer, Joseph J. Eron, Wayne Holman, Myron S. Cohen, et al. (2021) Molnupiravir, an Oral Antiviral Treatment for COVID-19. Version 1. medRxiv. Preprint. Retrieved from https://doi.org/10.1101/2021.06.17.21258639 DOI: https://doi.org/10.1101/2021.06.17.21258639
How to Cite
Copyright (c) 2021 Haghamad Allzain, Yassir Hamadalnil
This work is licensed under a Creative Commons Attribution 4.0 International License.
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.